2-bromo-2-oxoacetic acid ethyl ester | 74100-43-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-bromo-2-oxoacetic acid ethyl ester
• 英文别名: ethyl 2-bromo-2-oxoacetate；oxalic acid ethyl ester bromide；Oxalsaeure-aethylester-bromid
• CAS: 74100-43-9
• 化学式: C₄H₅BrO₃
• 分子量: 180.986
• InChiKey: OKOVEHLSBNFOHB-UHFFFAOYSA-N

物化性质

• 沸点：
  150-152 °C
• 密度：
  1.6226 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-bromo-2-oxoacetic acid ethyl ester 、 苯胺 生成 草酸乙酯
  参考文献：
  名称：

  Tschelinzew; Jessafow, Zhurnal Obshchei Khimii, 1932, vol. 2, p. 222

  摘要：

  DOI：
• 作为产物：
  描述：

  草酸二乙酯 在 五溴化磷 作用下， 生成 2-bromo-2-oxoacetic acid ethyl ester
  参考文献：
  名称：

  Tschelinzew; Jessafow, Zhurnal Obshchei Khimii, 1932, vol. 2, p. 222

  摘要：

  DOI：

文献信息

• 一种沙利度胺类似物
  申请人：无锡福祈制药有限公司

  公开号：CN107722006A

  公开（公告）日：2018-02-23

  本发明提供了一种有下式(Ⅰ)表示的化合物或其药学上可接受的盐；本发明所述揭示的沙利度胺类似物，能够有效且选择性地抑制JAK3并且阻断细胞因子信号和细胞因子诱导的基因表达，经试验证明，实现了对关节炎等疾病取得了更为良好的治疗效果。
• THIAZOLE OREXIN RECEPTOR ANTAGONISTS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20160185768A1

  公开（公告）日：2016-06-30

  The present invention is directed to thiazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the thiazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及噻唑化合物，其为促进睡眠的药物。本发明还涉及上述噻唑化合物在预防或治疗神经和精神障碍及疾病中的应用，其中促进睡眠的药物与促进睡眠的药物有关。本发明还涉及含有这些化合物的制药组合物。本发明还涉及这些制药组合物在预防或治疗与促进睡眠的药物有关的疾病中的应用。
• Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease
  作者：Dominique Lesuisse、André Malanda、Jean-François Peyronel、Yannick Evanno、Patrick Lardenois、Danielle De-Peretti、Pierre-Yves Abécassis、Pascal Barnéoud、Pascale Brunel、Marie-Claude Burgevin、Céline Cegarra、Florian Auger、Amélie Dommergue、Corinne Lafon、Luc Even、Joanna Tsi、Thy Phuong Hieu Luc、Antonio Almario、Anne Olivier、Marie-Noëlle Castel、Véronique Taupin、Thomas Rooney、Xavier Vigé

  DOI：10.1016/j.bmcl.2019.01.024

  日期：2019.4

  In the course of a programme aimed at identifying Nurr1/NOT agonists for potential treatment of Parkinson's disease, a few hits from high throughput screening were identified and characterized. A combined optimization pointed to a very narrow and stringent structure activity relationship. A comprehensive program of optimization led to a potent and safe candidate drug displaying neuroprotective and anti-inflammatory activity in several in vitro and in vivo models.
• [EN] HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES
  申请人：[en]BEIGENE, LTD.

  公开号：WO2023125681A1

  公开（公告）日：2023-07-06

  Disclosed herein is a compound of Formula (I) having the following structure for activating T cells, promoting T cell proliferation, and/or exhibiting antitumor activity, a method of using the compounds disclosed herein for treating cancer, and a pharmaceutical composition comprising the same.